Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma

Abstract

Background: Aberrant methylation of CpG islands in tumor cells in promoter regions is a critical event in non-small cell lung carcinoma (NSCLC) tumorigenesis and can be a potential diagnostic biomarker for NSCLC patients. The present study systemically and quantitatively reviewed the diagnostic ability of CDH13 methylation in NSCLC as well as in its subsets. Eligible studies were identified through searching PubMed, Web of Science, Cochrane Library and Embase. The pooled odds of CDH13 promoter methylation in lung cancer tissues versus normal controls were calculated by meta-analysis method. Simultaneously, four independent DNA methylation datasets of NSCLC from TCGA and GEO database were downloaded and analyzed to validate the results from meta-analysis. Results: Thirteen studies, including 1850 samples were included in this meta-analysis. The pooled odds ratio of CDH13 promoter methylation in cancer tissues was 7.41 (95% CI: 5.34 to 10.29, P < 0.00001) compared with that in controls under fixed-effect model. In validation stage, 126 paired samples from TCGA were analyzed and 5 out of the 6 CpG sites in the CpG island of CDH13 were significantly hypermethylated in lung adenocarcinoma tissues but none of the 6 CpG sites was hypermethylated in squamous cell carcinoma tissues. Concordantly, the results from other three datasets, which were subsequently obtained from GEO database consisting of 568 tumors and 256 normal tissues, also consisted with those from TCGA dataset. Conclusion: The pooled data showed that the methylation status of the CDH13 promoter is strongly associated with lung adenocarcinoma. The CDH13 methylation status could be a promising diagnostic biomarker for diagnosis of lung adenocarcinoma.

The SMART App: an interactive web application for comprehensive DNA methylation analysis and visualization

“…Abnormal DNA methylation patterns are found in every type of human cancer [3]. Many previous studies have shown that DNA methylation is involved in many aspects of carcinogenesis and provides potential biomarkers for evaluating the diagnosis and prognosis of cancer [4][5][6]. A recent study has also shown the association between DNA methylation and somatic copy number aberration, suggesting a much more complex mechanism beyond this modification [7].…”

Cadherin 13 Inhibits Pancreatic Cancer Progression and Epithelial-mesenchymal Transition by Wnt/β-Catenin Signaling

“…CDH13 is a newly identified cell adhesion molecule that is located on chromosome 16q24, a region often exhibiting loss of heterozygosity in cancer, including breast, prostate, colon and lung cancer [26][27][28][29][30]. The loss or low expression of CDH13 has been observed in a diverse range of cancer types, including cervical cancer, squamous cell carcinoma and melanoma [31][32][33].…”

Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma

“…Hypermethylation mediated downregulation of runt-related transcription factor 3 ( RUNX3 ) could induce docetaxel chemoresistance in LUAD [ 28 ]. CDH13 promoter is hypermethylated in LUAD and might be a potential diagnostic biomarker for diagnosis [ 29 ]. The heparan sulfate 6-O-endosulfatase ( SULF2 ) expression in NSCLC is negatively modulated by its DNA methylation in NSCLC.…”